- Home
- Europe Api Intermediates Market
Europe API Intermediates Market - Industry Trends and Forecast to 2028
- Published Date: September, 2022 | Report ID: CLS-282 | No of pages: 210 | Format:
Short Description
Europe API Intermediates Market, By Type (Veterinary Drug Intermediates Pharmaceutical / Bulk Drug Intermediates), Product (Bromo Compound, O-Benzyl Salbutamol, Hemisulfate, Oxirane, Bisoprolol Base, Chiral PCBHP, Pheniramine Base, Chlorpheniramine Base, Brompheniramine Base, Mepyramine/Pyrilamine Base, 6-Amino-1,3-Dimethyl Uracil, Theofylline, Acefylline, Xanthine, Nitriles, Others), Therapeutic Type (Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Disorders, Dermatology, Urology, Others), Customers (Direct Users/Pharma Companies, Traders/Wholesalers/Distributors, Associations/Govt. Institutions/Pvt Institutions), End User (API Manufacturer, Finished Product Manufacturer), Distribution Channel (Direct Tender, Retail Sales, Others), Country (Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe) Industry Trends & Forecast to 2028
Market Definition:
Active pharmaceutical ingredients are the substance or combination of substances intended to be used in the manufacturing of a drug product, which when used in the production of the drug, becomes an active pharmaceutical ingredient. Such substances are used to provide pharmacological activity. The final drug dosage form is formulated using the APIs and excipient but the APIs are formulated using the raw material which is known as intermediates. API intermediates are the kind of material that is produced in the process of API. The intermediates are the by-product of the active pharmaceutical ingredients and provide the same therapeutic activity as that of APIs. These intermediates are also used to cure different kinds of chronic diseases such as cancers, respiratory diseases, and infectious diseases among others.
Market Segmentation:
API intermediates market is segmented on the based on the basis of type, product, therapeutic type, customers, end users, and distribution channel.
On the basis of type, API intermediates market is segmented into veterinary drug intermediates pharmaceutical / bulk drug intermediates
On the basis of product, API intermediates market is segmented into bromo compound, O-benzyl salbutamol, hemisulfate, oxirane, bisoprolol base, chiral PCBHP, pheniramine base, chlorpheniramine base, brompheniramine base, mepyramine/pyrilamine base, 6-amino-1,3-dimethyl uracil, theofylline, acefylline, xanthine, nitriles, and others
On the basis of therapeutic type, API intermediates market is segmented into autoimmune diseases, oncology, metabolic diseases, ophthalmology, cardiovascular diseases, infectious diseases, neurology, respiratory disorders, dermatology, urology, and others
On the basis of customers, API intermediates market is segmented direct users/pharma companies, traders/wholesalers/distributors, and associations/govt. institutions/Pvt institutions
On the basis of end user, API intermediates market is segmented into API manufacturer, and finished product manufacturer
On the basis of distribution channel, API intermediates market is segmented into direct tender, retail sales, and others
Market Players:
The key market players for Europe API intermediates market are listed below:
HIKAL Ltd.
Cambrex Corporation
Ganesh-Group
AlzChem Group AG
Vasudha Pharma
Anyang General Chemical Co.,Ltd.
Sarex
Sandoo Pharmaceuticals and Chemicals Co., Ltd.
Atul Ltd
Sandoz International GmbH (a subsidiary of Novartis AG)
Aceto
Supriya Lifescience Ltd.
Vertellus
Dishman Carbogen Amcis Ltd
Sanofi
Divi's Laboratories Limited
AARTI INDUSTRIES LIMITED
Aurobindo Pharma
BASF SE
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 1.1 OBJECTIVES OF THE STUDY 1.2 MARKET DEFINITION 1.3 OVERVIEW OF EUROPE API INTERMEDIATES MARKET 1.4 LIMITATIONS 1.5 MARKETS COVERED 2 MARKET SEGMENTATION 2.1 MARKETS COVERED 2.2 GEOGRAPHICAL SCOPE 2.3 YEARS CONSIDERED FOR THE STUDY 2.4 CURRENCY AND PRICING 2.5 DBMR TRIPOD DATA VALIDATION MODEL 2.6 MULTIVARIATE MODELLING 2.7 TYPE LIFELINE CURVE 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 2.9 DBMR MARKET POSITION GRID 2.10 VENDOR SHARE ANALYSIS 2.11 MARKET TYPE COVERAGE GRID 2.12 SECONDARY SOURCES 2.13 ASSUMPTIONS 3 EXECUTIVE SUMMARY 4 PREMIUM INSIGHT 4.1 CURRENT SCENARIO OF IMPORT AND EXPORT OF API INTERMEDIATE 4.2 TENTATIVE PRODUCTION AND OPERATIONAL COSTS CALCULATIONS WHICH WILL ULTIMATELY LEAD TO FEASIBILITY OF THE PRODUCT MANUFACTURING 4.2.1 TENTATIVE LAND REQUIREMENT FOR A SUBSTANTIAL PRODUCTION CAPACITY PLANT SET-UP 4.3 EUROPE API INTERMEDIATES MARKET: 3C ANALYSIS-CHINA EFFECT 4.3.1 THE U.S.-CHINA TRADE WAR 4.3.2 INDO-CHINA GEOPOLITICAL ISSUES 4.3.3 CHINESE SLOWDOWN DUE TO E&C OVER THE YEARS 4.3.4 CHINESE SLOWDOWN DUE TO COVID-19 (CORONAVIRUS) 4.4 COST ANALYSIS 4.5 ANALYSIS ON CHINA API INTERMEDIATES: 4.5.1 CONCLUSION: 4.6 PORTERS FIVE FORCES MODEL 4.7 PESTEL ANALYSIS 4.8 EUROPE API INTERMEDIATES MARKET: REGULATORY 4.8.1 THE U.S. REGULATORY GUIDANCE FOR NON-CLINICAL SAFETY EVALUATION OF API INTERMEDIATES 4.8.2 CANADA REGULATORY GUIDANCE FOR API INTERMEDIATES 4.8.3 EUROPE REGULATORY SCENARIO FOR API INTERMEDIATES 4.8.4 JAPAN REGULATORY FOR API INTERMEDIATES 4.8.5 MIDDLE EAST AND AFRICA REGULATORY FRAMEWORK FOR API INTERMEDIATES 5 EUROPE API INTERMEDIATES MARKET: CONCLUSION 5.1 TOP PRODUCTS AND THERAPEUTIC AREAS 5.2 ADDITIONAL 6 CUSTOMER SENTIMENTS/INCLINATION TOWARDS FINDING ALTERNATE VENDOR SOURCE 7 LIST OF API OR FORMULATION COMPANIES WITH API INTERMEDIATE: 8 MARKET OVERVIEW 8.1 DRIVERS 8.1.1 HIGH BURDEN OF CHRONIC DISEASES 8.1.2 INCREASE IN AGING POPULATION 8.1.3 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURING 8.1.4 INCREASING DISEASE AWARENESS AND EDUCATION 8.1.5 RESEARCH AND DEVELOPMENT REGARDING PHARMACEUTICAL API AND THEIR INTERMEDIATES 8.2 RESTRAINTS 8.2.1 AVAILABILITY OF SUB-STANDARD AND COUNTERFEIT DRUGS 8.2.2 PRODUCT RECALLS 8.2.3 HIGH MANUFACTURING COST 8.2.4 STRINGENT GOVERNMENT REGULATIONS FOR API INTERMEDIATES 8.3 OPPORTUNITIES 8.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS 8.3.2 INCREASING HEALTHCARE EXPENDITURE 8.3.3 SOARING NUMBER OF API INTERMEDIATES MANUFACTURERS 8.3.4 RISE IN NUMBER OF CONTRACT MANUFACTURING ORGANIZATIONS (CMO) AND CONTRACT RESEARCH ORGANIZATIONS (CRO) 8.4 CHALLENGES 8.4.1 DISRUPTION IN THE SUPPLY CHAIN OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) DURING COVID-19 8.4.2 LACK OF WORKFORCE IN PHARMA INDUSTRIES 9 IMPACT OF COVID 19 ON EUROPE API INTERMEDIATES MARKET 9.1 IMPACT ON PRICE 9.2 IMPACT ON DEMAND 9.3 IMPACT ON SUPPLY CHAIIN 9.4 STRATEGIC DECISIONS FOR MANUFACTURERS AFTER COVID-19 TO GAIN COMPETITIVE MARKET SHARE 9.5 CONCLUSION 10 EUROPE API INTERMEDIATES MARKET, BY TYPE 10.1 OVERVIEW 10.2 PHARMACEUTICAL INTERMEDIATES/ BULK DRUG INTERMEDIATES 10.3 VETERINARY DRUG INTERMEDIATES 11 EUROPE API INTERMEDIATES MARKET, BY PRODUCT 11.1 OVERVIEW 11.2 NITRILES 11.3 BROMO COMPOUND 11.4 CHIRAL PCBHP 11.5 CHLORPHENIRAMINE BASE 11.6 BROMPHENIRAMINE BASE 11.7 PHENIRAMINE BASE 11.8 O-BENZYL SALBUTAMOL 11.9 BISOPROLOL BASE 11.10 HEMISULFATE 11.11 OXIRANE 11.12 MEPYRAMINE/PYRILAMINE BASE 11.13 THEOFYLLINE 11.14 ACEFYLLINE 11.15 XANTHINE 11.16 6-AMINO-1,3-DIMETHYL URACIL 11.17 OTHERS 12 EUROPE API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE 12.1 OVERVIEW 12.2 CARDIOVASCULAR DISEASES 12.3 METABOLIC DISEASES 12.4 INFECTIOUS DISEASES 12.5 RESPIRATORY DISEASES 12.6 NEUROLOGY 12.7 ONCOLOGY 12.8 AUTOIMMUNE DISEASE 12.9 DERMATOLOGY 12.10 OPHTHALMOLOGY 12.11 UROLOGY 12.12 OTHERS 13 EUROPE API INTERMEDIATES MARKET, BY CUSTOMERS 13.1 OVERVIEW 13.2 DIRECT USERS/PHARMA COMPANIES 13.3 TRADERS/WHOLESALERS/DISTRIBUTORS 13.4 ASSOCIATIONS/GOVT. INSTITUTIONS/PVT INSTITUTIONS 14 EUROPE API INTERMEDIATES MARKET, BY END USER 14.1 OVERVIEW 14.2 API MANUFACTURER 14.3 FINISHED PRODUCT MANUFACTURER 15 EUROPE API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL 15.1 OVERVIEW 15.2 DIRECT TENDER 15.3 RETAIL SALE 15.4 OTHERS 16 EUROPE API INTERMEDIATES MARKET BY GEOGRAPHY 16.1 EUROPE 16.1.1 GERMANY 16.1.2 U.K 16.1.3 ITALY 16.1.4 SPAIN 16.1.5 FRANCE 16.1.6 NETHERLANDS 16.1.7 RUSSIA 16.1.8 SWITZERLAND 16.1.9 TURKEY 16.1.10 AUSTRIA 16.1.11 NORWAY 16.1.12 HUNGARY 16.1.13 LITHUANIA 16.1.14 IRELAND 16.1.15 POLAND 16.1.16 REST OF ASIA PACIFIC 17 EUROPE API INTERMEDIATES MARKET: COMPANY LANDSCAPE 17.1 COMPANY SHARE ANALYSIS: EUROPE 18 SWOT ANALYSIS 19 COMPANY PROFILE 19.1 AUROBINDO PHARMA 19.1.1 COMPANY SNAPSHOT 19.1.2 REVENUE ANALYSIS 19.1.3 COMPANY SHARE ANALYSIS 19.1.4 PRODUCT PORFOLIO 19.1.5 RECENT DEVELOPMENTS 19.2 DIVIS LABORATORIES LIMITED 19.2.1 COMPANY SNAPSHOT 19.2.2 REVENUE ANALYSIS 19.2.3 COMPANY SHARE ANALYSIS 19.2.4 PRODUCT PORTFOLIO 19.2.5 RECENT DEVELOPMENTS 19.3 BASF SE 19.3.1 COMPANY SNAPSHOT 19.3.2 REVENUE ANALYSIS 19.3.3 COMPANY SHARE ANALYSIS 19.3.4 PRODUCT PORTFOLIO 19.3.5 RECENT DEVELOPMENT 19.4 CAMBRIX CORPORATION 19.4.1 COMPANY SNAPSHOT 19.4.2 COMPANY SHARE ANALYSIS 19.4.3 PRODUCT PORTFOLIO 19.4.4 RECENT DEVELOPMENTS 19.5 SANDOZ INTERNATIONAL GMBH (A SUBSIDIARY OF NOVARTIS AG) 19.5.1 COMPANY SNAPSHOT 19.5.2 REVENUE ANALYSIS 19.5.3 PRODUCT PORTFOLIO 19.5.4 RECENT DEVELOPMENT 19.6 ACETO 19.6.1 COMPANY SNAPSHOT 19.6.2 PRODUCT PORTFOLIO 19.6.3 RECENT DEVELOPMENT 19.7 HIKAL LTD. 19.7.1 COMPANY SNAPSHOT 19.7.2 REVENUE ANALYSIS 19.7.3 PRODUCT PORTFOLIO 19.7.4 RECENT DEVELOPMENTS 19.8 ALZCHEM GROUP AG 19.8.1 COMPANY SNAPSHOT 19.8.2 REVENUE ANALYSIS 19.8.3 PRODUCT PORTFOLIO 19.8.4 RECENT DEVELOPMENTS 19.9 VERTELLUS 19.9.1 COMPANY SNAPSHOT 19.9.2 PRODUCT CATEGORIES 19.9.3 RECENT DEVELOPMENTS 19.10 SANOFI 19.10.1 COMPANY SNAPSHOT 19.10.2 REVENUE ANALYSIS 19.10.3 PRODUCT PORFOLIO 19.10.4 RECENT DEVELOPMENTS 19.11 ATUL LTD 19.11.1 COMPANY SNAPSHOT 19.11.2 REVENUE ANALYSIS 19.11.3 PRODUCT PORTFOLIO 19.11.4 RECENT DEVELOPMENTS 19.12 AARTI INDUSTRIES LIMITED 19.12.1 COMPANY SNAPSHOT 19.12.2 REVENUE ANALYSIS 19.12.3 PRODUCT PORTFOLIO 19.12.4 RECENT DEVELOPMENT 19.13 VASUDHA PHARMA 19.13.1 COMPANY SNAPSHOT 19.13.2 PRODUCT PORTFOLIO 19.13.3 RECENT DEVELOPMENT 19.14 ANYANG GENERAL CHEMICAL CO., LTD. 19.14.1 COMPANY SNAPSHOT 19.14.2 PRODUCT PORFOLIO 19.14.3 RECENT DEVELOPMENT 19.15 DISHMAN CARBOGEN AMICS LTD 19.15.1 COMPANY SNAPSHOT 19.15.2 REVENUE ANALYSIS 19.15.3 PRODUCT PORFOLIO 19.15.4 RECENT DEVELOPMENTS 19.16 GANESH-GROUP 19.16.1 COMPANY SNAPSHOT 19.16.2 PRODUCT PORTFOLIO 19.16.3 RECENT DEVELOPMENTS 19.17 LEVACHEM COMPANY LIMITED 19.17.1 COMPANY SNAPSHOT 19.17.2 PRODUCT PORFOLIO 19.17.3 RECENT DEVELOPMENT 19.18 SANDOO PHARMACEUTICALS AND CHEMICALS CO., LTD. 19.18.1 COMPANY SNAPSHOT 19.18.2 PRODUCT PORTFOLIO 19.18.3 RECENT DEVELOPMENT 19.19 SAREX 19.19.1 COMPANY SNAPSHOT 19.19.2 PRODUCT PORTFOLIO 19.19.3 RECENT DEVELOPMENTS 19.20 SUPRIYA LIFESCIENCE LTD. 19.20.1 COMPANY SNAPSHOT 19.20.2 PRODUCT PORTFOLIO 19.20.3 RECENT DEVELOPMENT 20 QUESTIONNAIRE 21 RELATED REPORTSSegmentation
Short Description Europe API Intermediates Market, By Type (Veterinary Drug Intermediates Pharmaceutical / Bulk Drug Intermediates), Product (Bromo Compound, O-Benzyl Salbutamol, Hemisulfate, Oxirane, Bisoprolol Base, Chiral PCBHP, Pheniramine Base, Chlorpheniramine Base, Brompheniramine Base, Mepyramine/Pyrilamine Base, 6-Amino-1,3-Dimethyl Uracil, Theofylline, Acefylline, Xanthine, Nitriles, Others), Therapeutic Type (Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Disorders, Dermatology, Urology, Others), Customers (Direct Users/Pharma Companies, Traders/Wholesalers/Distributors, Associations/Govt. Institutions/Pvt Institutions), End User (API Manufacturer, Finished Product Manufacturer), Distribution Channel (Direct Tender, Retail Sales, Others), Country (Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe) Industry Trends & Forecast to 2028 Market Definition: Active pharmaceutical ingredients are the substance or combination of substances intended to be used in the manufacturing of a drug product, which when used in the production of the drug, becomes an active pharmaceutical ingredient. Such substances are used to provide pharmacological activity. The final drug dosage form is formulated using the APIs and excipient but the APIs are formulated using the raw material which is known as intermediates. API intermediates are the kind of material that is produced in the process of API. The intermediates are the by-product of the active pharmaceutical ingredients and provide the same therapeutic activity as that of APIs. These intermediates are also used to cure different kinds of chronic diseases such as cancers, respiratory diseases, and infectious diseases among others. Market Segmentation: API intermediates market is segmented on the based on the basis of type, product, therapeutic type, customers, end users, and distribution channel. On the basis of type, API intermediates market is segmented into veterinary drug intermediates pharmaceutical / bulk drug intermediates On the basis of product, API intermediates market is segmented into bromo compound, O-benzyl salbutamol, hemisulfate, oxirane, bisoprolol base, chiral PCBHP, pheniramine base, chlorpheniramine base, brompheniramine base, mepyramine/pyrilamine base, 6-amino-1,3-dimethyl uracil, theofylline, acefylline, xanthine, nitriles, and others On the basis of therapeutic type, API intermediates market is segmented into autoimmune diseases, oncology, metabolic diseases, ophthalmology, cardiovascular diseases, infectious diseases, neurology, respiratory disorders, dermatology, urology, and others On the basis of customers, API intermediates market is segmented direct users/pharma companies, traders/wholesalers/distributors, and associations/govt. institutions/Pvt institutions On the basis of end user, API intermediates market is segmented into API manufacturer, and finished product manufacturer On the basis of distribution channel, API intermediates market is segmented into direct tender, retail sales, and others Market Players: The key market players for Europe API intermediates market are listed below: HIKAL Ltd. Cambrex Corporation Ganesh-Group AlzChem Group AG Vasudha Pharma Anyang General Chemical Co.,Ltd. Sarex Sandoo Pharmaceuticals and Chemicals Co., Ltd. Atul Ltd Sandoz International GmbH (a subsidiary of Novartis AG) Aceto Supriya Lifescience Ltd. Vertellus Dishman Carbogen Amcis Ltd Sanofi Divi's Laboratories Limited AARTI INDUSTRIES LIMITED Aurobindo Pharma BASF SEMethodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.